Ftse Mib
34.339,32
0,55%
DAX
18.686,60
1,07%
S&P 500
5.214,08
0,51%
NASDAQ
16.346,26
0,27%
Bitcoin
62.906,57
-0,23%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. AMEX Citigroup Fdg (CTH) Citigroup Fdg (CTH) Notizie

CTH

Citigroup Fdg (CTH)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:AMEX:CTH
DataOraFonteTitoloSimboloCompagnia
15/08/201612:00GlobeNewswireCynapsus Announces Positive Opinion from Data and Safety Monitoring Board on Phase 3 Parkinson's Disease Clinical Study Allow...AMEX:CTHCitigroup Fdg
18/07/201622:10GlobeNewswireCynapsus Therapeutics Announces Positive Phase 3 Dose Titration Phase Results with APL-130277 for the Treatment of OFF Episod...AMEX:CTHCitigroup Fdg
30/06/201614:00GlobeNewswireCynapsus Therapeutics Enrolls Last Patient in Pivotal Phase 3 Efficacy Trial of APL-130277 to Treat OFF Episodes in Patients ...AMEX:CTHCitigroup Fdg
30/05/201608:00GlobeNewswireCynapsus Therapeutics Announces Data Presentations at the European Academy of Neurology Annual MeetingAMEX:CTHCitigroup Fdg
15/04/201612:00GlobeNewswireCynapsus Therapeutics Announces Data Presentations at the American Academy of Neurology Annual MeetingAMEX:CTHCitigroup Fdg
08/12/201508:00GlobeNewswireCynapsus Therapeutics Announces Positive Data Presentations at World Congress on Parkinson's Disease and Related Disorders Me...AMEX:CTHCitigroup Fdg
17/07/201422:15GlobeNewswireCynapsus Therapeutics Inc : Cynapsus Therapeutics Commences Phase 2 Clinical Trials in the United StatesAMEX:CTHCitigroup Fdg
08/07/201407:00GlobeNewswireCynapsus Therapeutics Inc. : Cynapsus Therapeutics Awarded Second Grant from The Michael J. Fox Foundation for Parkinson's Re...AMEX:CTHCitigroup Fdg
14/05/201412:00GlobeNewswireCynapsus Therapeutics Inc. : Cynapsus Announces No Buccal Mucosal Irritation in FDA Registration Study of APL-130277 for Park...AMEX:CTHCitigroup Fdg
24/04/201412:00GlobeNewswireCynapsus Therapeutics Inc. : Cynapsus Announces Positive Results of CTH-104 Clinical Study of APL-130277 for Parkinson's Dise...AMEX:CTHCitigroup Fdg
28/03/201411:00GlobeNewswireCynapsus Therapeutics Inc. : Cynapsus Announces Interim Summary Results of Human Healthy Volunteer Single 25mg Study for APL-...AMEX:CTHCitigroup Fdg
13/01/201412:00GlobeNewswireCynapsus Therapeutics Inc. : Cynapsus Announces Completion of Human Healthy Volunteer Crossover Study Results for APL-130277AMEX:CTHCitigroup Fdg
15/05/201307:00GlobeNewswireCynapsus Therapeutics Inc. : Cynapsus Therapeutics Publishes White Paper on Apomorphine for 'Off' Periods in Parkinson's Dise...AMEX:CTHCitigroup Fdg
24/03/200617:00PR Newswire (US)American Stock Exchange Lists Citigroup Funding Inc.'s 7.5% Sequins Linked to UnitedHealth Group Inc.AMEX:CTH
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:AMEX:CTH

La tua Cronologia

BIT
BPE
Bper Banca
BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
STLAM
Stellantis NV
BIT
ENEL
Enel
BIT
NEXI
Nexi S.p.A
BIT
BAMI
Banco BPM
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
PRY
Prysmian
BIT
ENI
Eni
BIT
RACE
Ferrari NV
BIT
LDO
Leonardo
BIT
STMMI
ST Microelectronics
BIT
FBK
Finecobank
BIT
TIT
Telecom Italia
BIT
SRG
Snam
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network